| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2012-09-26 | Pulmagen Therapeutics (UK) Teijin (Japan) | ADC3680 | asthma | development |
Respiratory diseases - Inflammatory diseases - Allergic diseases | Development agreement |
| 2012-09-24 | Hybrigenics (France) undisclosed American life sciences company (USA) | yeast two-hybrid (Y2H) screens | services |
Services contract | ||
| 2012-09-24 | Roche (Switzerland) Galaxy Biotech (USA) | antibodies targeting fibroblast growth factor 2 (FGF2) | undisclosed cancer | licensing |
Cancer - Oncology | Licensing agreement |
| 2012-09-21 | Ipsen (France) University of Manchester (UK) | exploration of the genetic data obtained in the Ipsen sponsored EPIGROW study | prevalence of IGF-1 deficiency in children with short stature | R&D |
Hormonal diseases - Endocrine diseases - Rare diseases | R&D agreement |
| 2012-09-20 | Sanofi (France) TB Alliance | novel compounds against tuberculosis | tuberculosis | R&D |
Infectious diseases | R&D agreement |
| 2012-09-20 | Centre for Bio Separation Technology (India) BIA Separations (Austria) | bioseparation platforms and technologies | collaboration |
Development agreement | ||
| 2012-09-20 | United Therapeutics (USA) Ascendis Pharma (Denmark-USA) | self-injectable Remodulin® (treprostinil) | pulmonary arterial hypertension | development |
Rare diseases - Cardiovascular diseases - Autoimmune diseases | Development agreement |
| 2012-09-20 | Curetis (Germany) Heraeus Medical (Germany) | novel Unyvero™ cartridge for the detection of pathogens and antibiotic resistances in implant & tissue infections | infections after knee and hip replacement surgeries | collaboration |
Infectious diseases | Development agreement |
| 2012-09-20 | Bind Biosciences (USA - MA) | nomination |
Nomination | |||
| 2012-09-19 | Evotec (Germany) NIH (USA) | NIH Small Molecule Repository (SMR) | services |
Services contract | ||
| 2012-09-19 | Abbott (USA), AstraZeneca (UK), Boehringer Ingelheim (Germany), BMS (USA), Eli Lilly (USA), GSK (UK), Johnson & Johnson (USA), Pfizer (USA - NY), Genentech a member of the Roche Group (USA-Switzerland), and Sanofi (France) | clinical study execution | R&D |
Clinical research agreement | ||
| 2012-09-17 | EMD Millipore (USA), the Life Science Division of Merck KGaA (Germany) - iPS Academia (Japan) | induced pluripotent stem (iPS) cell patent portfolio | licensing |
Technology - Services | Licensing agreement | |
| 2012-09-17 | GE Healthare (USA) VTT Technical Research Centre of Finland (Finland) | biomarkers to predict Alzheimer\'s disease | Alzheimer's disease | R&D |
Neurodegenerative diseases | R&D agreement |
| 2012-09-13 | Helsinn (Switzerland) DARA BioSciences (USA) | Gelclair® | oral mucositis | commercialisation |
Cancer - Oncology | Commercialisation agreement |
| 2012-09-13 | Oncodesign (France) Sanofi (France) | Nanocyclix® technology | R&D |
Cancer - Oncology | R&D agreement | |
| 2012-09-12 | CMC Biologics (Denmark - USA) Innomedica (Finland) | services |
Production agreement | |||
| 2012-09-12 | Ampio Pharmaceuticals (USA) Ethypharm (France) | Zertane™ | premature ejaculation | production |
Production agreement | |
| 2012-09-11 | Summit (UK) BMS (USA) | Seglin™ technology | licensing |
Licensing agreement | ||
| 2012-09-10 | PolyTherics (UK) Pro Bono Bio (UK) | improved blood factors (TheraPEG™ Factor IX, TheraPEG™ Factor VIII, TheraPEG™ Factor VIIa) | R&D |
Hematological diseases - Genetic diseases - Rare diseases | R&D agreement | |
| 2012-09-10 | AstraZeneca (UK) The Broad Institute (USA) | new chemical compounds targeting bacterial and viral infections | bacterial infections, viral infections | R&D |
Infectious diseases | R&D agreement |
